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A B S T R A C T 
There is an increased evidence for treating hypertension by a combination of two or more drugs. 
Increasing the number of daily intake of tablets has been reported to negatively affect the 
compliance by patients. Therefore, numerous fixed dose combinations (FDCs) have been 
introduced to the market. However, the inherent rigid nature of FDCs does not allow titration 
of the dose of each single component for individual patient needs. In this work, flexible dose 
combinations of two anti-hypertensive drugs in a single bilayer tablet with a range of doses 
were fabricated using dual 3D printer. Enalapril malate (EM) and hydrochlorothiazide (HCT) 
loaded filaments were produced via hot-melt extrusion (HME). Computer software was utilized 
to design sets of oval bi-layer tablet of individualised doses. Thermal analysis and x-ray 
diffractometry (XRD) indicated that HCT remained crystalline in the polymeric matrix whilst 
EM was in the amorphous form. The interaction between anionic EM and cationic methacrylate 
polymer may have contributed to a drop in the glass transition temperature (Tg) of the filament 
and obviated the need for a plasticiser. Across all tablet sets, the methacrylate matrix provided 
similar in vitro drug release profiles despite difference in dose and layer thickness. This 
dynamic dosing system maintained the advantages of fixed dose combinations while providing 
a superior flexibility of dosing range, hence offering an optimal clinical solution to 
hypertension therapy in a patient-centric healthcare service. 
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1. Introduction 
The use of fixed dose combinations (FDCs) to enhance or simplify the treatment and to enhance 
patient compliance is a common approach in the management of long term conditions e.g. type 
2 diabetes, HIV and hypertension (Bangalore et al., 2007; Desai et al., 2013). The history of 
combining multiple drugs in fixed doses dates back to 1950s; where the first combination was 
lunched as combined antihypertensive treatment (Wofford, 1997). At present, hypertension is 
often treated using several multiple drug classes, that are clinically used as dual or triple 
combinations (Wan et al., 2014). 
FDCs offer a myriad of benefits in treatment of hypertension; improving adherence (Castellano 
et al., 2014; Laurent et al., 2004) and reducing number of tablets intake. Hence, they facilitate 
a simplified streamlined schedule. Moreover, combining two or more therapeutics at lower 
doses can offer superior clinical output than single agent in maximal dose (Garber et al., 2003; 
Haak et al., 2012). In addition, FDCs can offer more cost-effective therapeutic option than 
monotherapy (Bell, 2013).  For instance, FDCs has lower cost in comparison to individual 
drugs as the cost of manufacturing, packaging and distribution is lowered (Desai et al., 2013; 
Gupta and Ramachandran, 2016).  
Although convenient, the system is often too rigid to accommodate to changing an individual 
patient’s needs e.g. the dose titration is particularly challenging for FDCs in a clinical setup 
(Xu et al., 2012) . For instance, if the prescriber identified the necessity to adjust the dose of 
one component in the FDC, one commonly used solution is the replacement of FDC with two 
separate dosage forms. In general, the doses in FDCs are designed to cover general population 
and hence they are less capable to meet the needs of small number of patients (Sleight et al., 
2006).  
3D printing is an emerging platform that offers many benefits in case of medicines 
personalisation (Alhnan et al., 2016; Prasad and Smyth, 2016). For instance, a dosage form can 
be fabricated according to the individual patient’s need with reduced number of steps involved 
in manufacturing while excluding the need of the expensive designated facilities (Skowyra et 
al., 2015).  Extrusion based 3D printing is capable of making a polypill with distinct release 
profiles (Khaled et al., 2015a, d). Although the technique offers the advantage of operation at 
room temperature, it often requires a long printing and drying time (typically 25 min and 24 h 
per tablet respectively)(Khaled et al., 2015a). It also mandates a significant compromise 
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between the viscosity of extruded materials, the size of the nozzle and the resolution of the 
finished product. 
The low cost and widely used FDM 3D printers, however, offered a new and more accessible 
opportunity for on-demand fabrication of a ready-to-use tablets/caplets, with flexible doses of 
drugs of extended release (Goyanes et al., 2014; Goyanes et al., 2015a; Pietrzak et al., 2015; 
Skowyra et al., 2015; Tagami et al., 2017) as well as immediate release profiles (Li et al., 2017; 
Okwuosa et al., 2016; Sadia et al., 2016).  
Although dual 3D printing has been reported for multilayer or core-shell fabrication to achieve 
dual drug or enteric drug release (Goyanes et al., 2015c; Okwuosa et al., 2017), there has been 
no previous report for fixed combination dose control in dual printing. This might be a 
reflection of the significant challenges often associated with dual FDM 3D printing; 
compatibility of the two materials, adhesion of printed layers in addition to the co-ordination 
of printing heads. These contributed to the difficulty of controlling drug dose in these multi-
drug dosage forms.  
Controlling the dose of 3D printed tablets might also raise a challenge in single head FDM 3D 
printing. Hot melt extrusion (HME) has been used to compound a filament as feed for FDM 
3D printing. Changing drug loading in based filaments, however, would significantly impact 
the plasticity as well as drug release pattern. As FDM 3D printing process is particularly 
sensitive to changes in plasticity and rheological properties of the filament, it is hence of 
paramount importance to craft a filament so the printer can fabricate structures of a similar 
release profile from wide range of doses. 
Therefore, the aims of this work are: i) to engineer a filament of wide range of drug contents 
and high compatibility with FDM 3D printing, ii) to utilise a low cost dual FDM 3D printer to 
achieve a dynamic dose combinations of two hypertensive drugs i.e. hydrochlorothiazide 
(HCT) and enalapril maleate (EM), and iii) to maintain similar release profile from individual 
or bi-layered system. 
2. Materials and methods 
2.1.Materials 
Tri-calcium phosphate (TCP), hydrochlorothiazide (HCT) and triethyl citrate (TEC) were 
purchased from Sigma-Aldrich (UK). Enalapril maleate (EM) was acquired from Kemprotec 
Ltd. (Cumbria, UK). Eudragit EPO was donated by Evonik Industries (Darmstadt, Germany). 
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2.2.Preparation and optimisation of filaments 
For single HCT tablets, drug loaded filaments were compounded with increasing percentages 
of HCT (X) (i.e. X= 0 (blank), 2.5, 5, 7.5, 10, 12.5, 25 or 50%). TCP (non-melting component) 
was employed as a substitute of HCT in each of the formulation to maintain incorporated solids 
content relative to the polymer. The final ratios of the formula were Eudragit EPO: TEC: HCT: 
TCP (46.75:3.25: X: 50-X), where X is the percentage of HCT in the filament. The nozzle size 
in this case was 1.25mm. 
For bilayer tablets, two types of filaments were extruded containing either HCT or EM. HCT 
filaments (25% HCT) were produced at ratio: Eudragit EPO: TEC: HCT: TCP (46.75:3.25: 25: 
25) as described above. 
In case of EM, two filaments with different levels of plasticizer (TEC 3.25% and 2.5%) were 
initially produced using a 1.25 mm nozzle and ratios of EPO: TEC: EM: TCP 46.75:3.25:15:35 
or 47.50:2.50:15: 35 respectively. However, these filaments were deemed too flexible and 
incompatible with FDM 3D printing process. Hence, a third filament with no plasticizer 
(without TEC) was produced at ratio EPO: EM: TCP 35:15:50 respectively using 1 mm nozzle 
head.   
All filaments were then extruded using a HAAKE MiniCTW counter flow twin screw hot melt 
extruder (Karlsruhe, Germany). The materials were accurately weighed (10 g), mixed in pestle 
and mortar for 5 min, and then fed and extruded through HME at 100 °C.  
2.3.Design and printing of tablets 
Tablets were fabricated with HME based filaments using a dual FDM 3D printer, Makerbot 
Replicator 2X (Makerbot Industries, LLC, USA). The templates were designed using 
Autodesk® 3ds Max Design 2016 software version 18.0 (Autodesk, Inc., USA). The design 
was saved in a stereolithography (.stl) file format and was imported to the 3D printer’s 
software, MakerWare Version Version 2.4.0.17 (Makerbot Industries, LLC, USA). Two sets 
of tablets were printed: 
 
i) Single HCT tablets. In order to assess the release profile of the tablets of wide range of drug 
concentration, a series of tablet of identical dimensions (12 x 4.7 x 4.63 mm) has been printed 
for each HCT loading (2.5, 5, 7.5, 10, 12.5, 25 or 50%). 
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ii) HCT-EM Bi-layer. Six sets of bilayer tablets were fabricated with the combination of all 
doses, i.e. HCT: EM 25:5, 25:10, 25:20, 12.5:5, 12.5:10 or 12.5: 20 mg:mg. The Lower layer 
(first layer to be printed) was fabricated using EM filament while the upper layer was based on 
25% HCT filament. 
In order to achieve these doses, tablets of identical length and width (x=12 and y=6 mm) were 
printed while the height (z) was adjusted to allow the control of the printed volume of each 
layer and in turn its final mass and dose. The dose was calculated as: 
D1 =0.25 W1 and D2 = 0.15 W2 
where D1 and D2 are the individual doses of HCT and EM, and W1 and W2 are the weight of 
layer containing 25% HCT or 15% EM respectively.  
The tablets were printed (n=4) and a linear curve was plotted between the volume and mass of 
the tablets.  
  W1 = D1/0.25 = 1.4275 V1 - 5.5707 
  W2 = D2/0.15 =1.5682 V2 - 8.1756 
Where V1 and V2 are the volume of the HCT and EM layer in the bi-layer tablet. 
The final dimensions of the layers to achieve the target dose are shown in Table 1. 
2.4.Thermal analysis 
Samples (5 mg) of raw materials and filaments were placed in TA aluminium pans 40 μL 
(standard) and pin holed lids and analysed using differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA). For DSC analysis, a differential scanning calorimeter DSC 
Q2000 (TA Instruments, Elstree, Hertfordshire, UK) was used. Samples were heated at a rate 
of 10 °C/min, from -50 to 280 °C preceded by a 1 min isotherm at -50 °C. The analysis was 
carried out under a purge of nitrogen at 50 mL/min. The collected data were analysed using a 
TA Universal Analysis 2000 v 4.5A software (TA Instruments, Elstree, Hertfordshire, UK).  
TGA analysis was carried out using a TGA Q500 (TA Instruments, Hertfordshire, UK). 
Samples of raw materials and filaments (10 mg approx.) were placed in a 40μL aluminium 
pans and were heated from 25 to 500 °C at a rate of 10 °C/min under nitrogen flow of 60 
mL/min.  
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In order to assess the impact of long term filament residence in hot nozzle during dual FDM 
3D printing, drugs (as received) and filaments with HCT and EM at concentrations of 25% and 
15% respectively were analysed by a thermo-scan from 25 to 140 °C with an isotherm of 30 
min at the 3D printing temperature (135 °C). The changes in the mass of samples were then 
analysed using TA Universal Analysis 2000 v 4.5A software (TA Instruments, Elstree, 
Hertfordshire, UK).  
2.5. X-ray diffractometer (XRD) 
 XRD analysis was carried out for raw materials, filaments and tablets using powder X-ray 
diffractometer, D2 Phaser with Lynxeye (Bruker, Germany). A scan was run from 2θ = 7° to 
50° with 0.1° step width and a 1s time count over 60 min. The divergence and scatter slits were 
1mm and 0.6mm respectively. The X-ray wavelength was 0.154 nm using a Cu source, the 
voltage of 30kV and filament emission of 10 mA. 
2.6.FT-IR Spectra measurements 
FT-IR measurement for raw materials, filaments and tablets was carried out using Nicolet 5700 
FT-IR spectrophotometer (Thermo Nicolet, Waltham, USA).  The spectra were scanned 
between 4000 and 500 cm-1 at a resolution of 2 cm-1 using 128 accumulations/scan.  
2.7.Characterisation of tablets 
To analyse the impact of high temperature on drug after HME and 3D Printing, the tablets were 
assessed for drug content. Tablets (n=3) were randomly selected from each set and weighed. 
Each tablet was then placed in 1000 mL volumetric flask containing 0.1 M HCl and sonicated 
for 2 h. The solutions were then filtered using 0.22 mm Millex-GP syringe filters (Merck 
Millipore, USA) in a 1 mL vial. Simultaneous quantification was then carried out using an 
Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) equipped with Kinetex 
C18 column (100 X 2.1 mm, particle size 2.6 mm) (Phenomenex, Torrance, USA). The mobile 
phase was acetonitrile: water (adjusted to pH 3 with o-phosphoric acid) and was measured at 
230 nm. A gradient method was used for the quantification of drugs in HPLC (Water pH 3: 
acetonitrile 95:5 for 0-3 min, 95:50 to 50:50 from 3 to 8 min, 95:5 from 8.01 to 14 min) with a 
stop time of 14 min.  
2.8.In vitro drug release from 3D printed tablets 
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In vitro drug release study was carried out using USP II Erweka DT600 dissolution tester 
(Erweka GmbH, Heusenstamm, Germany). For dissolution tests, tablets (n=3) from each of the 
sets: HCT: EM 5:12.5, 10:25 and 20:25 mg were placed in dissolution vessels containing 900 
mL of 0.1M HCl. The paddle speed was set to 50 rpm while the temperature was maintained 
at 37 °C. The samples were collected at 0, 5, 10, 15, 20, 25, 30, 40, 50 and 60 min using 5 mL 
Leur-Lock syringes. The samples were then filtered out in 2 mL HPLC vial through Millex-
HA 0.45 mm filters. The medium was then replenished with 4 mL of 0.1M HCl kept at same 
temperature. The quantitative analysis was then carried out using the HPLC protocol specified 
above.  
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3. Results and discussion 
The proposed dynamic dose dispenser is based on dual 3D printer head, each nozzle is loaded 
with individual loaded filament and dose is controlled by varying the thickness of each layer 
in the tablet (Fig. 1). To achieve this, a universal filament system for immediate release (Sadia 
et al., 2016) was adapted to include two antihypertensive drugs: EM and HCT. Firstly, the 
flexibility of the method to comprise different concentration of HCT has been investigated by 
varying drug concentration from 2.5% to 50% w/w. 
TGA studies showed no significant weight loss within the range of HME and 3D printing 
temperatures for all HCT filaments (Fig. 2A). DSC thermographs showed a Tg range of 22.9-
35°C across all ratios of HCT and were compatible with FDM 3D printing process (Fig 1B). 
This suggests that the drug had a limited plasticising impact on filaments. As Eudragit EPO 
degrades >250 oC, it was not possible to detect the melting point of HCT (Tm= 267 
oC) in both 
filament thermographs 
XRD analysis were used to confirm the physical form of HCT in the filament (Fig. 3), the 
diffraction peaks of HCT (as received) at 2theta = 16.65°, 19.13°, 20.95° and 24.64° were 
typical for HCT crystals (Khaled et al., 2015a). The presence of intensity peak at 2theta =19.13o 
in all HCT filaments indicated that HCT remained in crystalline form after undergoing through 
the thermal processing of HME. The use of TCP as a complimentary filler to replace HCT 
allowed the production of filament of consistent properties. In vitro release drug from identical 
size tablets showed no significant difference of percentage of drug release at T=30 min 
(p>0.05) (Fig. 4). This is of particular importance as it provides an alternative to controlling 
the dose of the 3D printed tablet by changing the size of the tablet, as previous reports indicated 
that surface area have a directly impact on its release pattern (Goyanes et al., 2015b; Pietrzak 
et al., 2015; Skowyra et al., 2015).  
TGA of EM (as received) showed low weight loss within the temperature of HME and 3D 
printing processes (100 and 135 oC) (Fig. 5A). EM loaded filaments demonstrated a slight level 
of weight loss (up to 3%) across the different ratios of plasticiser. EM loaded filaments were 
initially produced using similar plasticiser concentrations of that used with HCT (TEC 2.5% 
and 3.25% w/w) and yielded filaments of glass transition temperature (Tg) values <15 °C (Fig 
5B). This rendered the filament excessively flexible to be compatible with the FDM 3D printing 
procedure. Highly flexible filament is prone to frequent bending and deformation within gears 
that feed the hot nozzle of the FDM 3D printer. Since the drop in the Tg suggests that EM had 
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a plasticising effect on the methacrylic polymer, a new formulation was adapted by the removal 
of plasticizer (0 % TEC). By relying on drug’s plasticizing capacity, the resultant filament 
showed a Tg of 50 
oC (Fig. 5B), the latter proved more suitable for FDM 3D printing process.  
On the other hand, the absence of melting peak of EM at 145 oC suggested that EM was in 
amorphous state within both the filament and the tablet. This suggest that amorphous form 
integrity of EM were maintained following the 3D printing process. XRD patterns of EM (as 
received) showed intensity peaks at 2theta= 5.2°, 10.41° and 20.65°, which are typical of EM 
crystals (Kiang et al., 2003). These peaks were absent in the filaments hence confirmed that 
the EM was in amorphous form within EM filament. The high level of miscibility of Eudragit 
E and EM might be related to the opposite charge of the anionic malate and the cationic 
polymer chains. 
FTIR spectrum for Eudragit EPO showed peaks at 2770 and 2822 cm−1 corresponding to the 
absorption band of non-protonated dimethylamine of the polymer (Fig. S1), the filament 
showed a depression in these bands and hence suggest that EM neutralized the polymer. FTIR 
spectrum EM showed a band at 1750 cm-1 can be observed in both drug and physical mixture 
but disappeared in the filament and tablets. The band at 1750 cm-1 represents the stretching of 
C=O group (Ip and Brenner, 1987). The disappearance of this in the filament and tablets might 
indicate the carboxylic group of EM has interacted with the amino group of Eudragit EPO. 
These data indicate the cationic amino groups of Eudragit EPO and the carboxylic group of 
maleate (Ramirez-Rigo et al., 2014; Wang et al., 2004). Such an interaction between Eudragit 
E and anionic molecules has been used for the formation of molecules condensation (Guzman 
et al., 2012)  and solid complexes (Quinteros et al., 2011; Ramirez-Rigo et al., 2014) with the 
purpose of optimizing drug release or enhancing oral bioavailability. 
In dual FDM 3D printing, two thermal nozzles are orchestrated to extrude the filament in 
alternative fashion to fabricate multi-material structures. Hence while one filament is being 
processed through the nozzle, the other is held at elevated temperature in the second nozzle. 
Therefore, a retraction function has been introduced to many dual printing software to mitigate 
this effect. It is therefore important to assess the thermal stability of the filament at the printing 
temperature (135oC) for a prolonged time. Both filaments were subjected to a 30-min isotherm 
at 135°C to analyse the impact of prolonged thermal exposure on weight loss. The data showed 
that both HCT as well as HCT filament were stable at this temperature without significant 
weight loss (Fig 6 A1,A2). However, both EM (as received) and EM loaded filament showed 
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a weight loss under the same conditions (Fig 6 B1,B2), which suggested that prolonged 
exposure of EM to an elevated temperature during dual 3D printing might result in thermal 
degradation. Hence, the lower layer in the bi-layer structure of the tablet (which was printed 
first) was chosen to contain EM in order to minimise the period of exposure of EM to an 
elevated temperature of the printing process.  
Six sets of bilayer tablets with distinctive dose of EM and HCT were printed. The drug content 
of each layer were controlled by variating the thickness of individual drug layer within the 
structure (Fig. 1 A). Drug contents study was carried out in the filaments containing 25% HCT 
and 15% EM followed by 3D printed bilayer tablets (Table 2). The target dose were achieved 
for the majority of the tablet sets, however, increased deviation was noted particularly in low 
strength tablets. Such variation could be mitigated by improving the consistency of the mixing 
and applying a tight control on the filament diameter.  
The design of the bilayer tablets and an image of an exemplar tablet are shown in Figs. 7A, B, 
SEM images indicated that both drug layers were composed of 200 μm layer (Figs. 7C,D). It 
is interesting to highlight that HCT layer in the tablet was dominated with visible pores and 
embedded particles, while EM layers had a smoother surface and were more fused. On the 
other hand, Raman imaging indicated the consistent distribution of the drugs within each layer 
(Fig. 7E). 
In vitro drug release pattern from 3 sets of bilayer tablets are shown in Fig. 8, all the tablets 
released over 85% of both drugs within the first 30 min. Although the methodology is not 
identical, the release pattern is comparable to compendial requirements (Convention, 2007). It 
is interesting to note, however, that despite the distinctive difference in solubility of the two 
drugs [722mg/L  (Yalkowsky and R.M., 1992) and 25 000 mg/L (Budavari et al., 1996) for 
HCT and EM respectively], the release for both drugs were similar. This could be attributed to 
that fact that drug release is mainly regulated by the erosion of methacrylate polymeric matrix. 
Following tablet contact with acid medium, the cationic polymer ionises and dissolves in the 
medium (Dierickx et al., 2012), hence allowing both drugs to be released at similar rates. 
In these tablets, drug release was similar across different doses and layer thickness. The 
independence of drug release from drug loading is of particular advantage in practice, when 
the dose of one or both drugs in the bilayer tablet are sought to be modified without affecting 
drug release pattern and potentially therefore oral bioavailability. Patients who need secondary 
prevention post myocardial infarction, for instance, may need to increase their ACE inhibitor 
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while ensuring that the diuretic dose is kept constant (National Clinical Guideline Centre, 
2013). (Centre, 2013) 
In summary, we have reported the fabrication of bilayer tablets to achieve a new option of 
hypertensive patients (dose combination with dynamic dosing system). In a future scenario, 
physicians will be able to modify the dose for instance in response to patient’s clinical data 
while maintaining a single dose and without the need to change direction to the patient or 
request tablet splitting. 
4. Conclusion 
We demonstrated the use of dual 3D printing to achieve a dynamic dose dispensing. This 
dispensing system holds the advantages of fixed dosage combinations while offering a 
flexibility on dosing in a drug combination, hence ensuring that patient’s individual needs are 
continuously fulfilled. Despite differences in model drug miscibility in the polymer base, FDM 
3D-printing-compatible filaments were engineered via the manipulation of plasticiser level and 
the addition of inert non-melting component. This demonstrates the potential flexibility of the 
system. 
The use of methacrylate based bi-layer tablet system offers covering a wide range of drug 
loading (within the filament) and was tolerant to changing dose and layer thickness without 
affecting drug release from the 3D printed bi-layer tablets. Each tablet was printed with dual 
drugs and distinct dose combinations. In the future, utilizing such a low cost dynamic dosing 
system for antihypertensive combinations can potentially improve clinical outcomes and 
patient’s experience. 
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Table 1 Dimensions, volume and expected mass and dose of the HCT and EM layers in bi-layer tablets. 
 Dose Dimensions Volume   
(mm3) 
Expected 
weight (mg) 
Expected 
dose EM 
(mg) 
Expected dose HCT (mg) 
X  
(mm) 
Y  
(mm) 
Z  
(mm) 
Dose 1 12 6 1.6 90.5 112  - 24.6 
Dose 2 12 6 0.8 45.24 55.93  - 12.5 
Dose 1 12 6 0.6 33.9 41.9 5.53 -  
Dose 2 12 6 1.1 62.2 76.9 10.2 - 
Dose 3 12 6 2.2 124 154 20.3 -  
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Table 2 Layer dimensions, filament contents, target and achieved doses and dose efficiency of 3D printed tablets. 
  Drug Layer dimensions 
(X x Y x Z) (mm) 
Filament content 
(%)  ± SD 
Target dose 
(mg) 
Achieved dose 
(mg) AV± SD 
 
Bilayer Table I Enalapril layer 12 x6 x 0.6  94.42±0.56 5 4.93±0.56 
Hydrochlorothiazide layer 12 x6 x 0.8  92.35±2.45 12.5 11.73±0.36 
Bilayer Table II Enalapril layer 12 x 6 x 0.6  89.69±9.15 5 5.66±0.15 
Hydrochlorothiazide layer 12 x 6 x 1.6  91.98±2.73 25 25.82±0.68 
Bilayer Table III Enalapril layer 12 x 6 x 1.1  89.69±9.15 10 9.76±0.57 
Hydrochlorothiazide layer  12 x 6 x 0.8  91.98±2.73 12.5 12.95±1.07 
Bilayer Table IV Enalapril  12 x 6 x 1.1  89.69±9.15 10 9.64±0.13 
Hydrochlorothiazide  12 x 6 x 1.6  91.98±2.73 25 24.17±0.96 
Bilayer Table V Enalapril 12 x 6 x 2.2  96.98±1.39 20 20.11±0.64 
Hydrochlorothiazide 12 x 6 x 0.8  95.12±5.09 12.5 12.33±0.28 
Bilayer Table VI Enalapril  12 x 6 x 2.2  96.98±1.39 20 19.30±1.56 
Hydrochlorothiazide  12 x 6 x 1.6  95.12±5.09 25 24.85±3.03 
 
